You are here: Home » Reuters » News
Business Standard

Pfizer, Astellas prostate cancer drug promising in late-stage trial


By Divya Grover(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.Pfizer said the drug, Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival in men with ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, September 14 2017. 20:59 IST